Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

SG&A

Legal contingencies

Goodwill impairment

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Illumina

Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through the Core Illumina segment, which serves customers in the research, clinical and applied markets fields, and enables the adoption of a variety of genomic solutions. The firm's products include instruments, kits and reagents, selection tools, and software and analysis. Its services include sequencing and microarray services, proactive instrument monitoring, and instrument services, training, and consulting. The company was founded by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock, and Mark S. Chee in April 1998 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Illumina reports robust earnings, eyes GRAIL divestiture and market expansion

Illumina's strong financial performance in Q4 2022 and full-year revenue, driven by instrument placements and successful product launches, positions the company for continued growth.
Challenges such as margin decline, potential divestiture of GRAIL, and significant investment in clinical trials need to be managed strategically for sustained profitability.
Opportunities lie in revenue growth projections, NovaSeq X's market acceptance, GRAIL's product expansion, and continued FDA collaboration for product credibility.
Overall, Illumina's focus on innovation, market expansion, and operational efficiency sets a positive trajectory for future growth and market leadership.

Illumina surpasses Q1 revenue expectations, eyes margin improvement

Illumina's Q1 performance exceeded expectations with strong clinical demand and key product milestones driving revenue growth.
Despite challenges like Russia headwinds and regulatory uncertainties, Illumina aims for margin improvement and sustained revenue growth.
Opportunities lie in cost reduction, gross margin improvement, and product innovations to drive future growth and profitability.
Overall, Illumina's strategic focus on clinical markets and cost efficiencies positions it for continued success and market leadership.

Illumina adjusts revenue guidance for 2023 amidst challenges and opportunities

Illumina faces challenges in revenue growth for 2023 but remains committed to margin improvement. The company is navigating through cautious customer behaviors and challenges in China while focusing on innovation and cost reduction. Opportunities lie in strong customer interest in new products and the long-term potential of the China market.

Illumina faces revenue challenges in Q3 2023 amidst growth opportunities

Illumina's Q3 performance was steady, but challenges in the macroeconomic environment and GRAIL's performance pose concerns for future revenue and growth.
Despite these challenges, Illumina remains committed to driving top-line growth through innovation and operational excellence, aiming for swift decisions on GRAIL's future.
Opportunities lie in margin improvements, growth potential compared to peers, and strategic decisions for GRAIL funding, indicating a path forward amidst challenges.
The company faces headwinds in consumables sales and Nova X transition but sees a positive outlook for long-term market positioning and growth opportunities.

Illumina reports $1.12B revenue, eyes multiomics expansion opportunities

Illumina's Q4 performance showed revenue growth and successful NovaSeq X launch, but faced challenges in Greater China.
The company's strengths lie in customer relationships, innovation pipeline, and plans to enter the multiomics space.
Opportunities include expanding into proteomics, driving fleet expansions, and developing MRD assay applications.

Illumina surpasses Q1 revenue expectations, eyes growth in XLEAP chemistry

Illumina's Q1 performance exceeded expectations with strong revenue and service growth. The company's focus on innovation, strategic partnerships, and customer-centricity positions it well for future growth. While facing challenges in operating expenses and market dynamics, Illumina sees opportunities in XLEAP chemistry adoption and increased instrument orders.

Illumina reports solid Q2 revenue amidst regional challenges and innovation

Illumina's Q2 2024 performance reflected strong Core revenue driven by sequencing consumables and placements.
While facing challenges in regional revenue declines, the company's strengths in genomics support and innovation remain key.
Opportunities for growth exist through customer adoption trends, operational enhancements, and strategic initiatives.

Illumina reports robust Q3 earnings, eyes genomics innovation for growth

Illumina's Q3 performance was solid, with revenue meeting expectations and strong operational metrics.
While facing challenges in certain regions, the company's focus on innovation and customer collaboration bodes well for future growth.
Opportunities in new product introductions and genomic solutions signal a promising outlook for Illumina's market position.

Revenue

Cost of revenue

Gross profit

Operating expenses

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Illumina Inc (NASDAQ:ILMN) shares sank 11% in pre-market trading on Friday after the gene-testing company reduced its annual profit forecast for the second straight quarter, citing weakness in demand for its sequencing instruments, consumables and services.  Illumina said it sees its full year 2023 earnings per share (EPS) of between $0.60 to $0.70, falling short of the $0.80 analyst consensus forecast.

Illumina stock drops on another earnings warning

Illumina (ILMN) reports solid earnings in the third quarter of 2023 amid a challenging macro environment.

Illumina (ILMN) Q3 Earnings Surpass Estimates, '23 View Cut

Illumina, Inc. (NASDAQ:ILMN ) Q4 2023 Earnings Conference Call November 9, 2023 5:00 PM ET Company Participants Salli Schwartz - Vice President of Investor Relations Jacob Thaysen - Chief Executive Officer Joydeep Goswami - Chief Financial Officer, Chief Strategy and Corporate Development Officer Conference Call Participants Vijay Kumar - Evercore ISI Dan Brennan - TD Cowen Puneet Souda - Leerink Partners Dan Arias - Stifel Michael Ryskin - Bank of America Tejas Savant - Morgan Stanley Dan Leonard - UBS Sung Ji Nam - Scotia Bank Kyle Mikson - Canaccord Catherine Schulte - Baird Conor McNamara - RBC Capital Markets Rachel Vatnsdal - J.P. Morgan Operator Good day, ladies and gentlemen, and welcome to the Third Quarter 2023 Illumina Earnings Conference Call.

Illumina, Inc. (ILMN) Q3 2023 Earnings Call Transcript

U.S. genetic testing Illumina on Thursday trimmed its annual profit forecast for the second straight quarter, hurt by weakness in demand for its sequencing instruments, consumables and services.

Illumina cuts annual profit forecast for second straight quarter

Shares of Illumina Inc. ILMN, -3.36% fell after hours on Thursday after the maker of DNA-sequencing technology cut its full-year sales and profit outlook. The company said it now expected full-year sales to fall 2% to 3%, compared with a forecast in August for around 1% growth, and an adjusted per-share profit of 60 to 70 cents, lower than prior expectations for 75 cents to 90 cents a share.

Illumina shares fall as company cuts forecasts

Welcomed new CEO Jacob Thaysen, Ph.D., who started with Illumina on September 25, 2023 With respect to GRAIL, continue to proceed quickly: retained advisors and preparing for sale and capital markets transaction options for GRAIL, including filing a Form 10, in accordance with the European Commission's divestiture order; a Board special committee has been established to expedite decisions; in parallel, ongoing appeals preserve flexibility for any divestiture of GRAIL and future transactions Revenue of $1.12 billion for Q3 2023, flat compared to Q3 2022 (up 1% on a constant currency basis) and down 5% from Q2 2023 Shipped 97 NovaSeq X instruments in Q3 2023; now expect to ship 330 to 340 instruments for fiscal year 2023 GAAP diluted loss per share of $(4.77) for Q3 2023, which included goodwill and intangible impairments of $821 million related to the GRAIL segment, compared to GAAP diluted loss per share of $(24.26) for Q3 2022, which included goodwill impairment of $3.91 billion related to the GRAIL segment Non-GAAP diluted earnings per share of $0.33 for Q3 2023, compared to non-GAAP diluted earnings per share of $0.34 for Q3 2022 Now expect fiscal year 2023 consolidated revenue to decrease 2% to 3% from 2022, including Core Illumina revenue to decrease 3% to 4% from 2022 and GRAIL revenue at the low end of the $90 million to $110 million range Now expect GAAP diluted loss per share of $(6.67) to $(6.57) for fiscal year 2023, which includes goodwill and intangible impairments of $821 million related to the GRAIL segment Now expect non-GAAP diluted earnings per share of $0.60 to $0.70 for fiscal year 2023 SAN DIEGO , Nov. 9, 2023 /PRNewswire/ -- Illumina, Inc. (Nasdaq: ILMN) ("Illumina" or the "company") today announced its financial results for the third quarter of fiscal year 2023, which include the consolidated financial results for GRAIL.

Illumina Reports Financial Results for Third Quarter of Fiscal Year 2023

LOS ANGELES, CA / ACCESSWIRE / November 9, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Illumina, Inc. ("Illumina" or "the Company") (NASDAQ:ILMN) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Stratasys board breached its fiduciary duties to shareholders.

GRAIL SHAREHOLDER ALERT: The Schall Law Firm Announces it is Investigating Claims Against Illumina, Inc. and Encourages Investors with Losses to Contact the Firm

Enphase Energy

JD.com

Moderna

Sirius XM Holdings Inc

Walgreens

One knock against Wall Street analysts is they're too bullish, especially when it comes to Nasdaq 100 stocks. No matter the market conditions, they seem able to find the silver lining.

6 Nasdaq 100 Stocks Down 40% or More that Will Soar As Much 367%

Veracyte

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte Announces In Vitro Diagnostic Agreement with Illumina to Broaden Availability of Its Tests for Patients Globally.

Veracyte Announces In Vitro Diagnostic Agreement with Illumina to Broaden Availability of Its Tests for Patients Globally

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Illumina (ILMN), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2023.

Seeking Clues to Illumina (ILMN) Q3 Earnings? A Peek Into Wall Street Projections for Key Metrics

Illumina (ILMN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Illumina (ILMN) Q3 Earnings Expected to Decline

TSO 500 ctDNA Version 2 delivers faster turnaround time, greater analytical sensitivity, more streamlined workflow, further enabling precision medicine. SAN DIEGO , Nov. 1, 2023 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced a new generation of its distributed liquid biopsy assay for genomic profiling.

Illumina launches advanced liquid biopsy assay to enable comprehensive genomic profiling of solid tumors

LOS ANGELES--(BUSINESS WIRE)---- $ILMN--The Law Offices of Frank R. Cruz Announces Investigation of Illumina, Inc. (ILMN) on Behalf of Investors.

The Law Offices of Frank R. Cruz Announces Investigation of Illumina, Inc. (ILMN) on Behalf of Investors

Albemarle

Comerica

Dollar General

Estee Lauder

Etsy

KeyCorp

Paramount Global

Insulet

SolarEdge Technologies

Investors fearing a brutal stock market crash are still waiting with dread. But it's already arrived for a group of battered S&P 500 stocks.

The Dreaded Market Crash Is Already Here For 14 Stocks

Ligand Pharmaceuticals

Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Ligand Pharmaceuticals (LGND) or Illumina (ILMN). But which of these two companies is the best option for those looking for undervalued stocks?

LGND vs. ILMN: Which Stock Is the Better Value Option?

Illumina is the global leader in gene sequencing. Illumina is at a tremendous discount to its inherent value. This is a jewel of a business that you want to own for the long-term, and this is the perfect entry point.

Illumina: Mispriced Jewel At Maximum Pessimism

LOS ANGELES, CA / ACCESSWIRE / October 19, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Illumina, Inc. ("Illumina" or "the Company") (NASDAQ:ILMN) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Stratasys board breached its fiduciary duties to shareholders.

GRAIL INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Illumina, Inc. and Encourages Investors with Losses to Contact the Firm

Activist-investor Carl Icahn said his firm had sued current and former board directors at Illumina concerning the acquisition of gene-sequencing company Grail , the Financial Times reported on Tuesday.

Activist Icahn sues Illumina board over Grail acquisition - FT

Illumina Inc. ILMN, -1.10% responded Friday to an order it received Thursday from the European Commission directing the company to divest its $7.1 billion acquisition of cancer-test maker Grail. Illumina said it has 12 months to divest Grail, with a potential three-month extension, and “will be permitted to explore a range of structures including, but not limited to, a third-party sale or a capital markets transaction.

Illumina responds to EC Grail divestiture order

Illumina said on Friday it would divest cancer test maker Grail in 12 months, according to the terms of the order by the European Commission, if it does not win its challenge in court.

Illumina to divest cancer test maker Grail if it does not win challenge in EU court

SAN DIEGO , Oct. 13, 2023 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN), has received an order from the European Commission (EC) directing the company to divest GRAIL. Receipt of the order is an important next step in evaluating divestiture options for GRAIL.

Illumina responds to European Commission's divestiture order

Illumina Inc (NASDAQ:ILMN), a genetic testing company, has been ordered by EU antitrust regulators to sell Grail after closing its takeover of the cancer test maker before securing their approval. In a statement, the European Commission said it has adopted, under the EU Merger Regulation, “restorative measures requiring Illumina to unwind its completed acquisition of Grail.

Illumina ordered by European Commission to sell cancer test maker Grail

U.S. genetic testing company Illumina has been ordered by EU antitrust regulators to sell cancer test maker Grail after it completed the deal before securing their approval.

Illumina ordered by EU antitrust regulators to sell Grail

Illumina Inc said on Wednesday it will divest Grail if the company loses the final appeals in U.S. or European courts.

Illumina to divest Grail if it loses final court appeals

SAN DIEGO , Oct. 11, 2023 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) posted a stewardship-focused presentation for investors on the Events & Presentations section of its investor relations website, investor.illumina.com, on Wednesday, October 11, 2023. Members of Illumina's Board of Directors and senior management may use this presentation during meetings with investors.

News for Illumina Stock (ILMN)